Efficacy and safety of gelatine tannate for the treatment of acute gastroenteritis in children: protocol of a randomised controlled trial

Dorota Michałek, Maciej Kołodziej, Zofia Konarska, Hania Szajewska, Dorota Michałek, Maciej Kołodziej, Zofia Konarska, Hania Szajewska

Abstract

Introduction: Worldwide, acute gastroenteritis in children, usually caused by viruses, leads to considerable morbidity and mortality. The treatment is aimed at preventing and treating dehydration, promoting weight gain after rehydration, and reducing the duration and severity of diarrhoea. Effective and inexpensive interventions that could add to the effect of oral rehydration therapy are of interest. Recently, in many European countries, gelatine tannate is being widely marketed for treating acute gastroenteritis. Gelatine tannate is a complex of tannic acid, which possesses astringent and anti-inflammatory properties, and a protective gelatine. Currently, there is no evidence to support the use of gelatine tannate for treating acute gastroenteritis in children and only scant evidence to support the use of gelatine tannate in adults. We aim to assess the efficacy of gelatine tannate for the treatment of acute gastroenteritis in children.

Methods and analysis: This will be a blind, placebo-controlled, randomised trial. Children younger than 5 years of age with acute gastroenteritis defined as a change in stool consistency to loose or liquid form (according to the Bristol Stool Form scale or Amsterdam Stool Form scale) and/or an increase in the frequency of evacuations (typically ≥ 3 in 24 h), lasting for no longer than 5 days, will be recruited. A total of 72 children will be randomised to receive either gelatine tannate (children younger than 3 years of age will receive 250 mg, 4 times/day, and those older than 3 years of age will receive 500 mg, 4 times/day) or matching placebo for 5 days. The primary outcome measure is the duration of diarrhoea.

Ethics and dissemination: The Bioethics Committee approved the study protocol. The findings of this trial will be submitted to a peer-reviewed paediatric journal. Abstracts will be submitted to relevant national and international conferences.

Trial registration number: NCT02280759; Pre-results.

Keywords: RCT; antidiarrheal drugs; children; diarrhea.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

References

    1. Ogilvie I, Khoury H, Goetghebeur MM et al. . Burden of community-acquired and nosocomial rotavirus gastroenteritis in the pediatric population of Western Europe: a scoping review. BMC Infect Dis 2012;12:62 10.1186/1471-2334-12-62
    1. Van Damme P, Giaquinto C, Huet F et al. . Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004–2005: the REVEAL study. J Infect Dis 2007;195(Suppl 1):S4–16. 10.1086/516714
    1. Guarino A, Ashkenazi S, Gendrel D et al. . European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr 2014;59:132–52. 10.1097/MPG.0000000000000375
    1. Bueno L, Sekkal S, Theodoru V et al. . Undissociated gelatine tannate reduces intestinal leakiness and mucosa inflammation by forming a protective biofilm: results from in-vitro and in-vivo studies. United European. Gastroenterol J 2013;l:A75–6.
    1. Chung KT, Stevens SE Jr, Lin WF et al. . Growth inhibition of selected food-borne bacteria by tannic acid, propyl gallate and related compounds. Lett Appl Microbiol 1993;17:29–32. 10.1111/j.1472-765X.1993.tb01428.x
    1. Scalbert A. Antimicrobial properties of tannins. Phytochemistry 1991;30:3875–83. 10.1016/0031-9422(91)83426-L
    1. Oi H, Matsuura D, Miyake M et al. . Identification in traditional herbal medications and confirmation by synthesis of factors that inhibit cholera toxin-induced fluid accumulation. Proc Natl Acad Sci USA 2002;99:3042–6. 10.1073/pnas.052709499
    1. Frasca G, Cardile V, Puglia C et al. . Gelatine tannate reduces the proinflammatory effects of lipopolysaccharide in human intestinal epithelial cells. Clin Exp Gastroenterol 2012;5:61–7. 10.2147/CEG.S28792
    1. Esteban Carretero J, Durbán Reguera F, López-Argüeta Alvarez S et al. . A comparative analysis of response to ORS (oral rehydration solution) vs. ORS+gelatin tannate in two cohorts of pediatric patients with acute diarrhea. Rev Esp Enferm Dig 2009;101:41–8. 10.4321/S1130-01082009000100005
    1. Allegrini A, Costantini M. Gelatine tannate for the treatment of acute diarrhoea in adults. J Gastroint Dig Syst 2012:2;3.
    1. Ruszczynski M, Urbanska M, Szajewska H. Gelatin tannate for treating acute gastroenteritis: a systematic review. Ann Gastroenterol 2014;27:121–4.
    1. Benson H, Friedman R. Harnessing the power of the placebo effect and renaming it “remembered wellness”. Annu Rev Med 1996;47:193–9. 10.1146/annurev.med.47.1.193
    1. The WHO Child Growth Standards.
    1. Schnadower D, Tarr PI, Gorelick MH et al. . Validation of the modified Vesikari score in children with gastroenteritis in 5 US emergency departments. J Pediatr Gastroenterol Nutr 2013;57:514–19. 10.1097/MPG.0b013e31829ae5a3

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi